Proton pump inhibitor-induced hypomagnesemia: A new challenge
نویسندگان
چکیده
منابع مشابه
Hypomagnesemia associated with a proton pump inhibitor.
Severe hypomagnesemia is a serious clinical condition. Proton pump inhibitor (PPI) induced hypomagnesemia has been recognized since 2006. In March 2011 the U.S. Food and Drug Administration advised that long-term use of PPI can induce hypomagnesemia. We report the first Japanese case of hypomagnesemia associated with chronic use of PPIs in a 64-year-old man hospitalized for nausea, bilateral an...
متن کاملHypomagnesemia and proton-pump inhibitors.
INTRODUCTION Proton pump inhibitors (PPIs) have been linked to clinically symptomatic hypomagnesemia. AREAS COVERED We searched Medline database in all languages using 'proton-pump inhibitors, magnesium, hypomagnesemia and hypomagnesemic hypoparathyroidism' as search terms and other articles were identified through searches of the files of the authors and reference lists from relevant article...
متن کاملHypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with anothe...
متن کامل[Hypomagnesemia induced by proton pump inhibitors, diarrhea, and lactose intolerance].
ypomagnesemia is an uncommon biochemical change in utpatients, but may be detected in up to 12% of hositalized patients, in whom factors such as total and nteral nutrition, diuretic use, diarrhea, hypoalbuminemia, nd nephrotoxic drugs (antibiotics, chemotherapeutic, etc.) lay a significant role in its occurrence. Symptoms related to ypomagnesemia usually occur with serum magnesium levels ower t...
متن کاملDexlansoprazole – a new-generation proton pump inhibitor
Dexlansoprazole modified release (MR) is an R-enantiomer of lansoprazole and a new-generation proton pump inhibitor exhibiting high efficacy in the treatment of symptoms and lesions associated with erosive oesophagitis caused by gastroesophageal reflux disease (GERD). The dual release of the active ingredient - in the duodenum and the small intestine - makes it possible to achieve two peak conc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Nephrology
سال: 2012
ISSN: 2220-6124
DOI: 10.5527/wjn.v1.i6.151